13 reports

THE DRUG CANDIDATE ACTS BY TARGETING DIPEPTIDASE-##.

  • Antifungal
  • Blood Disease
  • Oncology
  • Therapy
  • Bristol-Myers Squibb Company

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Chronic Disease
  • Oncology
  • Respiratory Disease
  • United States
  • Product Initiative

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Blood Disease
  • Monoclonal Antibody
  • Oncology
  • Therapy
  • United States

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Oncology
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Monoclonal Antibody
  • Oncology
  • United States
  • Product Initiative

About ## percent of people who have food allergies are allergic to more than one food.

  • Monoclonal Antibody
  • Oncology
  • Respiratory Disease
  • United States
  • Product Initiative

Rituximab was well tolerated, and most adverse drug reactions were grade ##-## in severity.

  • Monoclonal Antibody
  • Oncology
  • Therapy
  • United States
  • Product Initiative

The molecules developed by Companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ##, ## and ## respectively.

  • Monoclonal Antibody
  • Oncology
  • Therapy
  • United States
  • Product Initiative

ABOUT ## PERCENT OF PEOPLE WHO HAVE FOOD ALLERGIES ARE ALLERGIC TO MORE THAN ONE FOOD.

  • Oncology
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

The drug candidate targets P/ neurokinin ## (NK##) receptors.

  • Antifungal
  • Oncology
  • United States
  • Product Initiative
  • Helsinn Group

The drug candidate targets P/ neurokinin ## (NK##) receptors.

  • Antifungal
  • Oncology
  • United States
  • Product Initiative
  • Helsinn Group

This explains the need for a high drug dose of IXF-## as supported by the findings of the recently published post-hoc analysis.

  • Monoclonal Antibody
  • Oncology
  • Therapy
  • United States
  • Product Initiative

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antifungal
  • Infectious Disease
  • Oncology
  • United States
  • SCYNEXIS, Inc.